Ajanta Pharma has received final approval of Zolmitriptan tablets (2.5mg, 5mg) from the U.S. Food and Drug Administration (FDA). Zolmitriptan is used in the acute treatment of migraine and is an equivalent generic version of Zomig1.
Zolmitriptan Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the U.S. market. To date, the United States Food & Drug Administration (U.S.FDA) has granted Ajanta Pharma 9 ANDA final approvals and 2 tentative approvals. Additional 15 ANDAs are under review with the FDA.
Ajanta Pharma is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.
